Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Authors: Veverka, Karen A., Thng, Steven T.G., Silverberg, Jonathan I., Armstrong, April W., Menezes, Josemund, Kaoukhov, Alexandre, Blauvelt, Andrew

Source: In Journal of the American Academy of Dermatology March 2024 90(3):504-511

Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials

Authors: Veverka, Karen A., Hansen, Jes B., Yaloumis, Maria, Kircik, Leon H., Gold, Linda Stein

Source: Journal of drugs in dermatology. 20(8):822-828

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN627286397&indx=1&recIds=ETOCRN627286397

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)

Authors: Gerdes, Sascha, Velasco, Manuel, Wu, Jashin J., Hubo, Mario, Veverka, Karen A.

Source: Journal of dermatological treatment. 32(8):883-893

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100135222381.0x000001&indx=1&recIds=ETOCvdc_100135222381.0x000001

Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.

Authors: Cevikbas, Ferda, Ward, Alison, Veverka, Karen A.

Source: BioDrugs; Nov2024, Vol. 38 Issue 6, p821-830, 10p

Subject Terms: IMMUNOGLOBULIN E, LACTATE dehydrogenase, ATOPIC dermatitis, THYMUS, SYMPTOMS

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis

Authors: Gold, Linda Stein, Hansen, Jes B., Patel, Dharm, Veverka, Karen A., Strober, Bruce

Source: In Journal of the American Academy of Dermatology July 2020 83(1):131-138

Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers

Authors: Cevikbas, Ferda, Ward, Alison, Firth, Carl, Veverka, Karen

Source: Clinical immunology. 253

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100194733614.0x000001&indx=1&recIds=ETOCvdc_100194733614.0x000001

Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis

Authors: Wu, Jashin J., Hansen, Jes B., Patel, Dharm S., Nyholm, Nanna, Veverka, Karen A., Swensen, Andrine R.

Source: Journal of medical economics. 23(6):641-649

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100124814637.0x000001&indx=1&recIds=ETOCvdc_100124814637.0x000001

Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis

Authors: Hansen, Jes B., Larsson, Thomas, Dunkelly-Allen, Nikeshia, Veverka, Karen A., Feldman, Steven R.

Source: Journal of drugs in dermatology. 19(8):756-762

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN624439751&indx=1&recIds=ETOCRN624439751

Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis

Authors: Veverka, Karen A., Patel, Dharm S., Anger, Tobias, Hansen, Jes B., Del Rosso, James, Kircik, Leon H.

Source: Journal of drugs in dermatology. 19(2):121-127

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN623002860&indx=1&recIds=ETOCRN623002860

Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

Authors: Wu, Jashin J., Veverka, Karen A., Lu, Minyi, Armstrong, April W.

Source: Journal of dermatological treatment. 30(5):454-460

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100086050593.0x000001&indx=1&recIds=ETOCvdc_100086050593.0x000001

The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment

Authors: Wu, Jashin J., Lu, Minyi, Veverka, Karen A., Smulders, Maartje, Papademetriou, Eros, Yu, Junhua, Feldman, Steven R.

Source: Journal of dermatological treatment. 30(5):446-453

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100086050524.0x000001&indx=1&recIds=ETOCvdc_100086050524.0x000001

Targeting type 2 immune activation beyond atopic dermatitis

Authors: Leung, Donald Y.M., Facheris, Paola, Veverka, Karen A., Cevikbas, Ferda, Guttman-Yassky, Emma

Source: In Annals of Allergy, Asthma & Immunology February 2024 132(2):121-123

Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis

Authors: Gorelick, Joe, Cantrell, Wendy, Kucera, Kristine, Veverka, Karen A., Gooding, Kara

Source: Journal of drugs in dermatology. 17(8):880-885

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN617281519&indx=1&recIds=ETOCRN617281519

Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study.

Authors: PATEL, DHARM S.¹, VEVERKA, KAREN A.¹, HANSEN, JES B.², YAMAUCHI, PAUL S.³, ALONSO-LLAMAZARES, JAVIER⁴, LEBWOHL, MARK⁵ lebwohl@aol.com

Source: Journal of Clinical & Aesthetic Dermatology. May2020, Vol. 13 Issue 5, p12-18. 7p.

Subject Terms: *FOAM, *SCALP, *PSORIASIS

53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial

Authors: Simpson, Eric, Gooderham, Melinda, Kircik, Leon, Armstrong, April W., Schlesinger, Todd, Del Rosso, James Q., Murrell, Dédée F., Thng, Steven, Szepietowski, Jacek C., Veverka, Karen A., Kaoukhov, Alexandre

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB194-AB194

Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats

Authors: Kim, Juhyun, Wang, Ronghua, Veverka, Karen A., Dalton, James T.

Source: Xenobiotica. 43(11):993-1009

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100103932497.0x000001&indx=1&recIds=ETOCvdc_100103932497.0x000001

Estrogen Receptor-β-selective Ligands Alleviate High-fat Diet- and Ovariectomy-induced Obesity in Mice

Authors: Yepuru, Muralimohan, Eswaraka, Jeetendra, Kearbey, Jeffrey D., Barrett, Christina M., Raghow, Sharan, Veverka, Karen A., Miller, Duane D., Dalton, James T., Narayanan, Ramesh

Source: In Journal of Biological Chemistry 8 October 2010 285(41):31292-31303

Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649

Authors: Wu, Jashin J., Hansen, Jes B., Patel, Dharm S., Nyholm, Nanna, Veverka, Karen A., Swensen, Andrine R.

Source: Journal of medical economics. 23(12):1501-1502

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100116160992.0x000001&indx=1&recIds=ETOCvdc_100116160992.0x000001

Treating benign prostate hyperplasia with SARMS

Treating muscle wasting with selective androgen receptor modulators